

## Oct 2016 – Jan 2017 Funded BioCanRx Projects

### Catalyst Projects (8)

Start Date	Project Title	Principal Investigator(s)	Total Project Funding
October 14, 2016	Optimizing a personalized infected cell vaccine (ICV) for peritoneal carcinomatosis	Auer, Rebecca Ottawa Hospital Research Institute	<b>BioCanRx funding: \$251,692</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>• Biodextris - \$50,000 (cash)</li> <li>• The Ottawa Hospital Foundation - \$50,000 (cash)</li> <li>• Turnstone Biologics (in-kind)</li> <li>• University of Ottawa - \$40,000 (cash)</li> </ul> <b>Total Funding: \$391,692</b>
		Diallo, Jean-Simon Ottawa Hospital Research Institute	
		Fergusson, Dean Ottawa Hospital Research Institute	
October 14, 2016	Validation and manufacturing of anti-BCMA-TACT cells for the treatment of multiple myeloma	Delisle, Jean-Sebastien Hôpital Maisonneuve-Rosemont (HMR), Université de Montréal	<b>BioCanRx funding: \$200,000</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>• Triumvira Immunologics - \$129,918 (cash)</li> <li>• Miltenyi Biotec - \$50,000 (in-kind)</li> <li>• HMR-CEMTL (CETC) - \$40,000 (in-kind)</li> </ul> <b>Total Funding: \$419,918</b>
		Bramson, Jonathan McMaster University	
January 17, 2017	New generation chimeric antigen receptors for improved adoptive T cell therapy for cancer	Hirano, Naoto Princess Margaret Cancer Centre, University Health Network	<b>BioCanRx funding: \$200,001</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>• Takara Bio - \$200,000</li> </ul> <b>Total Funding: \$400,001</b>
October 14, 2016	Infected Cell Vaccines in the Treatment of Acute Leukemia: Laying the Groundwork for a Clinical Trial	Kekre, Natasha Ottawa Hospital Research Institute	<b>BioCanRx funding: \$239,776</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>• Turnstone Biologics - \$10,000 (in-kind)</li> <li>• Bone Marrow Transplantation Foundation, The Ottawa Hospital - \$40,000 (cash)</li> <li>• The Ottawa Hospital Foundation - \$40,000 (cash)</li> </ul> <b>Total Funding: \$329,776</b>

January 17, 2017	Targeted radioligand (tRL) and checkpoint blockade for metastatic castrate resistant prostate cancer	Lum, Julian BC Cancer Agency University of Victoria	<b>BioCanRx funding: \$199,996</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>BC Cancer Foundation - \$164,944 (\$105,424 in-kind, \$59,520 cash)</li> <li>MedImmune - \$39,000 (in-kind)</li> <li>Telus Ride for Dad Prostate Cancer Fight Foundation - \$13,678 (cash)</li> <li>BC Cancer Agency - \$64,850 (in-kind)</li> </ul> <b>Total Funding: \$482,468</b>
		Benard, Francois BC Cancer Agency University of British Columbia	
		Minchinton, Andrew BC Cancer Agency, University of British Columbia	
April 1, 2017	Pre-clinical validation of anti-SIRP $\alpha$ antibodies anti-tumor efficacy through immuno-modulation of macrophages	Sidhu, Sachdev Donnelly Centre, University of Toronto	<b>BioCanRx funding: \$200,000</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>Ontario Ministry of Research and Innovation - \$216,262 (cash)</li> </ul> <b>Total Funding: \$416,262</b>
		Moffat, Jason Donnelly Centre, University of Toronto	
October 14, 2016	Bispecific T-cell engager antibodies targeting CD133+ brain tumor-initiating cells: A Novel Immunotherapy for Recurrent Glioblastoma	Singh, Sheila Stem Cell and Cancer Research Institute, McMaster University	<b>BioCanRx funding: \$100,000</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>Terry Fox Research Institute - \$100,000 (in-kind)</li> <li>Centre for the Commercialization of Antibodies and Biologics (in-kind)</li> </ul> <b>Total Funding: \$200,000</b>
		Moffat, Jason Donnelly Centre, University of Toronto	
October 14, 2016	Recombinant TCRs and peptide-MHC antibodies to target KRAS hotspot mutations in pancreatic cancer	Turcotte, Simon Centre Hospitalier de l'Université de Montréal	<b>BioCanRx funding: \$69,225</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>Institut du cancer Montréal - \$33,100 (\$12,500 cash, \$20,600 in-kind)</li> <li>Université de Montréal – Surgery Department - \$15,000 (cash)</li> <li>The Centre for Drug Research and Development - \$60,000 (in-kind)</li> <li>Research Chair Roger Des Groseillers - \$3,560</li> <li>Pancreas Centre BC - \$16,800</li> </ul> <b>Total Funding: \$197,685</b>
		Holt, Robert BC Cancer Agency, University of British Columbia, Simon Fraser University	

## Enabling Studies Projects (6)

Start Date	Project Title	Principal Investigator(s)	Total Project Funding
January 17, 2017	In vivo human therapeutic cell tracking using a [ <sup>19</sup> F]-perfluorocarbon cellular MRI contrast agent: Phase I feasibility and preliminary safety trial	Dekaban, Gregory Robarts Molecular Medicine, University of Western Ontario	<b>BioCanRx funding: \$43,500</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>Celsense Inc. \$32,750 (in-kind)</li> <li>Ontario Institute for Cancer Research (OICR) \$10,139 (cash)</li> <li>Dendreon Corp. \$2,625 (cash)</li> </ul> <b>Total Funding: \$89,014</b>
		Foster, Paula Robarts Research Institute, University of Western Ontario	
January 17, 2017	Oncolytic vaccinia virus for bladder cancer treatment: A phase I/II trial	Evans, David University of Alberta	<b>BioCanRx funding: \$226,054</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>Alberta Innovates - \$226,054 (cash)</li> </ul> <b>Total Funding: \$452,108</b>
January 17, 2017	Capacity building for Chimeric Antigen Receptor (CAR)-modified T cell therapies in Canada	Holt, Rob BC Cancer Agency, University of British Columbia, Simon Fraser University	<b>BioCanRx funding: \$1,244,375</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>BC Cancer Foundation - \$460,000 (cash)</li> <li>The Ottawa Regional Cancer Foundation - up to \$2,500,000 of anticipatory funding (cash)</li> </ul> <b>Total Funding: \$4,204,375</b>
January 17, 2017	Garbage to Gold: Expansion of Therapeutic Regulatory T Cells from Discarded Thymus	Levings, Megan University of British Columbia, BC Children's Hospital Research Institute	<b>BioCanRx funding: \$275,659</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>STEMCELL Technologies - \$60,876 (cash)</li> <li>BC Children's Hospital - \$336,400 (cash)</li> <li>Alberta Cell Therapy Manufacturing - \$42,150 (cash)</li> <li>CNTRP - \$32,000 (cash)</li> <li>StemCell Network - \$100,000</li> </ul> <b>Total Funding: \$847,085</b>
October 14, 2016	Adoptive T cell therapy targeting patient-specific driver mutations in	Nelson, Brad University of British Columbia	<b>BioCanRx funding: \$358,186</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>Canadian Cancer Society</li> </ul>

	lymphoma		Research Institute - \$224,225 (cash) <ul style="list-style-type: none"> <li>• Miltenyi Biotec - \$11,000 (cash)</li> <li>• BC Cancer Foundation - \$125,136 (cash)</li> </ul> <b>Total Funding: \$718,547</b>
October 14, 2016	Development of predictive companion biomarkers and therapeutic monitoring for hypermutant cancers to immune checkpoint inhibition	Tabori, Uri Hospital for Sick Children, The Arthur and Sonia Labatt Brain Tumour Research Centre, University of Toronto	<b>BioCanRx funding: \$744,996</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>• Bristol Myer Squibb - \$745,257 (cash)</li> </ul> <b>Total Funding: \$1,490,253</b>

### Clinical, Social and Economic Impact Program (2)

Start Date	Project Title	Principal Investigator(s)	Total Project Funding
January 17, 2017	Translational Cancer Immunotherapeutics: Improving the Design, Analysis, and Reporting of Preclinical Studies	Fergusson, Dean Ottawa Hospital Research Institute	<b>BioCanRx funding: \$196,093</b>  <b>Total Funding: \$196,093</b>
		Lalu, Manoj Ottawa Hospital Research Institute, University of Ottawa	
January 17, 2017	Getting better Outcomes with Chimeric Antigen Receptor T-cell therapy (GO-CART): A BioCanRx Research Excelerator to Safely and Effectively Translate CAR-T Cell Therapy for Hematological Malignancies	Lalu, Manoj Ottawa Hospital Research Institute, University of Ottawa	<b>BioCanRx funding: \$364,119</b> <b>Partner contributions:</b> <ul style="list-style-type: none"> <li>• Ottawa Methods Centre - \$50,000 (in-kind)</li> <li>• BC Cancer Agency – In-kind</li> <li>• Health Canada – In-kind</li> <li>• University of Manitoba – In-kind</li> <li>• University of Calgary – In-kind</li> <li>• Leukemia and Lymphoma Society of Canada – In-kind</li> </ul> <b>Total Funding: \$414,119</b>
		Fergusson, Dean Ottawa Hospital Research Institute	